This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Bayer for ProfessionalsYour Resource Portal

Angeliq
^®

(1mg estradiol hemihydrate and 2mg drospirenone)

What is Angeliq and what is it used for?

This medicine is a “fixed combination”. This means that the medicine is composed of two or more active substances that are already in clinical use.

Angeliq is used for relief of symptoms occurring after menopause and prevention of osteoporosis. This medicine is used in postmenopausal women with at least 12 months (1 year) since their last natural period.

Relief of symptoms occurring after menopause

During the menopause, the amount of the oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest (“hot flushes”). Angeliq alleviates these symptoms after menopause. Patients should only be prescribed Angeliq for symptoms that adversely affect quality of life.

Prevention of osteoporosis

After the menopause, some women may develop fragile bones (osteoporosis). Patients should discuss all available options with their doctor. If the patients is at an increased risk of fractures due to osteoporosis and other medicines are not suitable for them, they can use Angeliq to prevent osteoporosis after menopause.

How does Angeliq work?

Angeliq is a Hormone Replacement Therapy (HRT). It contains two types of female hormone, an oestrogen and a progestogen.

When making individualised treatment decisions for your patients, please refer to the Angeliq Summary of Product Characteristics for more information including other important clinical considerations before you prescribe.

Following initiation of therapy, physicians should undertake a careful appraisal of the risks and benefits at least annually and HRT should only be continued as long as the benefit outweighs the risk.